Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 5, 2026
- Novavax raised its 2026 adjusted total revenue guidance to $385 - $415 million after earning a $125 million milestone from Sanofi, while third-quarter revenue was $68 million and net loss was $31 million.
- 10-Q report · filed Nov 5, 2026
- Novavax reported revenue of $68.3 million and a net loss of $31.4 million, or $0.19 per share, for the three months ended September 30, 2026, versus a $202.4 million loss, or $1.25 per share, in 2025. R&D expenses fell to $52.4 million from $98.3 million.
The audio replay and transcript follow the call.